GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
iSERA Lifesciences Ltd

iSERA Lifesciences Reports Q2 FY27 Unaudited Financial Results

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 04 Nov 2026, 09:31 PM IST  ·  BSE ID: c4656a66-13ea-40fc-8e5c-ed3affbc1a8c
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest financial numbers, showing a loss and low income for the quarter.
🤖 AI Summary
  • iSERA Lifesciences approved standalone unaudited financial results for Q2 FY27 and half year ended September 30, 2026.
  • Net loss for Q2 FY27 was INR (13.11) Lakhs, with a total income of INR 7.88 Lakhs.
  • Basic earnings per share reported at INR (0.62) for the quarter ended September 30, 2026.
  • Cash and cash equivalents at the end of September 30, 2026, stood at INR 3.55 Lakhs.
  • The Board meeting commenced at 5:00 P.M. and concluded at 5:30 P.M. on November 4, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Net Profit/(Loss) for the period
(13.11) INR Lakhs
Not comparable — limited prior period data.
Total Income
7.88 INR Lakhs
Not comparable — limited prior period data.
Basic Earnings per Equity Share
(0.62) INR
Not comparable — limited prior period data.
Cash & Cash Equivalents at End of Year
3.55 INR Lakhs
Not comparable — limited prior period data.
🏢 How This Affects the Company
📈
Business Impact
The minimal revenue from operations and reliance on other income indicates a limited core business activity in the reported period.
💰
Financial Impact
The company recorded a net loss of INR (13.11) Lakhs in Q2 FY27 and negative cash flow from operating activities, leading to a significant reduction in cash and cash equivalents.
⚙️
Operational Impact
The reported expenses, including employee benefits and administrative costs, exceed the total income, suggesting operational challenges in achieving profitability.
⚠️
Risk Impact
The sustained net loss and negative cash flows raise concerns about liquidity and the company's ability to cover operating costs from its primary business activities.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported net loss of INR (13.11) Lakhs and the decline in the company's cash position.
🔍
Management Signal
The approval of these results signals management's disclosure of the company's financial performance for the period ended September 30, 2026.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for improvements in total income and profitability.
Subsequent cash flow statements — monitor trends in cash from operating activities.
Updates on business strategy — look for initiatives to improve revenue generation.
HIGH RISK Sustained net losses and negative cash flows raise concerns about the company's financial stability and operational viability.
💡 Investor Takeaway
iSERA Lifesciences reported a net loss of INR (13.11) Lakhs for Q2 FY27. Total income for the quarter was INR 7.88 Lakhs, with basic earnings per share at INR (0.62). Cash and cash equivalents reduced to INR 3.55 Lakhs as of September 30, 2026.
⚖️ Strengths & Concerns

⚠️ Concerns

  • iSERA Lifesciences reported a net loss of INR (13.11) Lakhs for Q2 FY27.
  • Cash and cash equivalents decreased significantly from INR 286.62 Lakhs at the beginning of the year to INR 3.55 Lakhs.
📅 Company Track Record
iSERA Lifesciences (formerly Covidh Technologies Ltd) previously informed BSE of board meetings on Nov 4, 2026, for Q2 FY27 results, Aug 7, 2026, for Q1 FY27 results, and May 21, 2026, for financial results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was iSERA Lifesciences' net profit/loss in Q2 FY27?
iSERA Lifesciences reported a net loss of INR (13.11) Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was the total income for iSERA Lifesciences in Q2 FY27?
The total income for iSERA Lifesciences in Q2 FY27, ended September 30, 2026, was INR 7.88 Lakhs.
What were the basic earnings per share for iSERA Lifesciences in Q2 FY27?
Basic earnings per equity share for iSERA Lifesciences in Q2 FY27 were INR (0.62) for the quarter ended September 30, 2026.
What was iSERA Lifesciences' cash and cash equivalents balance on September 30, 2026?
On September 30, 2026, iSERA Lifesciences had cash and cash equivalents totaling INR 3.55 Lakhs.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.